Drug resistance of leukemic blasts is correlated to event-free survival and might be predicted by mRNA expression of drug resistance-related proteins. Methotrexate (MTX) is an important component in the treatment of childhood leukemia. Mechanisms of MTX resistance include (1) decreased transport via the reduced folate carrier (RFC), (2) altered levels of target enzymes, eg dihydrofolate reductase (DHFR) and thymidylate synthase (TS), (3) decreased ratio of folylpolyglutamate synthetase (FPGS)/folylpolyglutamate hydrolase (FPGH). We designed competitive templates for each of these genes to measure mRNA expression by quantitative RT-PCR and normalized the expression to that of beta-actin. T-lineage acute lymphoblastic leukemia (T-ALL), relati...
Acute Lymphoblastic Leukemia (ALL) is the most widespread form of childhood cancer, and methotrexate...
Methotrexate (MTX) is not cytotoxic to patient-derived acute lymphoblastic leukemia (ALL) cells in t...
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphobla...
The ability of leukemia cells to accumulate methotrexate polyglutamate (MTXPG) is an important deter...
Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be c...
BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and ...
textabstractWe studied whether common polymorphisms in genes involved in folate metabolism aff...
BACKGROUND: Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with...
Cellular methotrexate (MTX) resistance may cause treatment failure in childhood common/preB-acute ly...
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the commonest of the childhood cancers, but thankful...
BACKGROUND: Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with...
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Although its prognosis conti...
Chemoresistance is an important factor in the treatment failure of childhood acute lymphoblastic leu...
Treatment failure in childhood acute lymphoblastic leukaemia (ALL) might be associated with methotre...
BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy in ...
Acute Lymphoblastic Leukemia (ALL) is the most widespread form of childhood cancer, and methotrexate...
Methotrexate (MTX) is not cytotoxic to patient-derived acute lymphoblastic leukemia (ALL) cells in t...
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphobla...
The ability of leukemia cells to accumulate methotrexate polyglutamate (MTXPG) is an important deter...
Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be c...
BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and ...
textabstractWe studied whether common polymorphisms in genes involved in folate metabolism aff...
BACKGROUND: Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with...
Cellular methotrexate (MTX) resistance may cause treatment failure in childhood common/preB-acute ly...
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the commonest of the childhood cancers, but thankful...
BACKGROUND: Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with...
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Although its prognosis conti...
Chemoresistance is an important factor in the treatment failure of childhood acute lymphoblastic leu...
Treatment failure in childhood acute lymphoblastic leukaemia (ALL) might be associated with methotre...
BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy in ...
Acute Lymphoblastic Leukemia (ALL) is the most widespread form of childhood cancer, and methotrexate...
Methotrexate (MTX) is not cytotoxic to patient-derived acute lymphoblastic leukemia (ALL) cells in t...
Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphobla...